undamentalytics Newsletter
Sign in

Krystal Biotech, Inc. income statement

In fiscal 2025, Krystal Biotech, Inc. reported revenue of $389m, up 33.9% on the year before, operating income of $161m (a 41.5% margin) and net income of $205m, or $6.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0051291389470
Research and development284246545860
Selling, general and administrative—7898114147156
General and administrative40—————
Operating income−68−145−11066161228
Interest expense100———
Income before tax−70−1401395189259
Income tax0026−1534
Net income−70−1401189205225
Diluted EPS−$3.13−$5.49$0.39$3.00$6.84$7.36
Diluted shares (average)22m25m28m30m30m31m
EBITDA−66−141−10572167234

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARQT vs KRYSCRMD vs KRYSARDX vs KRYSADMA vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Krystal Biotech, Inc.